- Introduction: The ISRIB Family Landscape
- ISR Pathway Mechanism: How ISRIB Works
- Stereochemistry: Trans vs CIS Isomers
- Trans-ISRIB: The Mature Workhorse Probe
- CIS-ISRIB: The Negative Control Isomer
- ISRIB A-15: The In Vitro Screening Specialist
- ISRIB A-17: The Premium In Vivo CNS Probe
- Comprehensive Four-Way Comparison
- Pricing & Market Positioning
- Selection Decision Guide
- Quality, Purity & Isomeric Control
- Frequently Asked Questions
- Conclusion
Introduction: The ISRIB Family Landscape
Since its discovery in 2013 by Carmela Sidrauski and Peter Walter at the University of California, San Francisco, ISRIB (Integrated Stress Response InhiBitor) has revolutionized the study of the integrated stress response (ISR) pathway. What began as a single compound has evolved into a family of probes — each engineered for a specific research context. Today, researchers face a critical choice: Trans-ISRIB, the mature and affordable workhorse; CIS-ISRIB, the inactive isomer used as a negative control; ISRIB A-15, the high-activity in vitro specialist; and ISRIB A-17, the premium in vivo CNS-targeted probe.
The selection is not merely a matter of budget. Choosing the wrong ISRIB variant can compromise experimental data, waste animal resources, or produce confounding artifacts that are difficult to untangle. A researcher running a 90-day neurodegeneration study with standard Trans-ISRIB may encounter inadequate brain drug exposure and inconsistent efficacy. Conversely, using ISRIB A-17 for a simple cell-based screening assay is an unnecessary expense when Trans-ISRIB at a fraction of the cost would suffice.
Trans-ISRIB is the mature, cost-effective probe for routine research (≥98% purity, ~$ per mg). CIS-ISRIB serves as the stereochemical negative control. ISRIB A-15 offers enhanced in vitro potency for screening. ISRIB A-17 is the premium in vivo probe with 2.1× brain exposure, 14-hour half-life, and IND-grade purity (≥99.5%) for chronic CNS studies.
This guide provides a systematic, multi-dimensional comparison of all four ISRIB variants — from molecular structure and stereochemistry to pharmacokinetics, pricing, and application matching — so you can make an informed procurement decision for your specific research needs.
ISR Pathway Mechanism: How ISRIB Works
The integrated stress response (ISR) is a conserved cellular signaling network that is activated by diverse stress conditions — including endoplasmic reticulum (ER) stress, amino acid deprivation, viral infection, and heme deficiency. Four kinases (PERK, GCN2, PKR, and HRI) converge on a single phosphorylation event: the phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) at serine 51. This phosphorylation globally suppresses cap-dependent protein translation while selectively upregulating ATF4, a transcription factor that activates stress-responsive genes.
While transient ISR activation is protective, chronic or excessive ISR activation is implicated in a wide range of pathological conditions — neurodegeneration (Alzheimer's, Parkinson's, ALS), traumatic brain injury, ischemic stroke, diabetes, and certain cancers. ISRIB reverses the translational suppression without interfering with the upstream kinase signaling, making it a uniquely valuable tool for dissecting the translational arm of the ISR from its transcriptional arm.
ISRIB's Molecular Target: eIF2B
All active ISRIB variants act on the same molecular target: eIF2B (eukaryotic initiation factor 2B), a guanine nucleotide exchange factor (GEF) that regenerates the active GTP-bound form of eIF2. When eIF2α is phosphorylated, it becomes a competitive inhibitor of eIF2B, locking the GEF in an inactive complex and stalling translation initiation. ISRIB binds to the interface of the eIF2B δ and ε subunits, stabilizing the decameric (Aαβγδε)2 complex and restoring its GEF activity even in the presence of phosphorylated eIF2α.
This mechanism is shared by all active ISRIB compounds. What differentiates the variants is not their target or mechanism, but their potency, pharmacokinetics, brain penetration, and physicochemical properties — factors that determine which experimental contexts each variant is best suited for.
All four ISRIB variants share the same molecular target (eIF2B) and mechanism of action. The differences that matter for probe selection are stereochemistry (trans vs cis), pharmacokinetic profile (half-life, BBB penetration), purity grade, and cost — not target specificity.
Stereochemistry: Trans vs CIS Isomers
ISRIB is a symmetric bis-glycolamide molecule containing a central carbon-carbon double bond that gives rise to geometric (E/Z) isomerism. The relative orientation of the two aromatic substituent groups across this double bond determines whether the molecule is the trans (E) or cis (Z) isomer.
Why Stereochemistry Matters
In the trans configuration, the two aromatic ring systems are positioned on opposite sides of the double bond, creating the extended, U-shaped molecular geometry that is optimal for binding the eIF2B δ/ε subunit interface. This geometry allows both glycolamide arms to simultaneously contact their respective binding pockets, achieving the high-affinity interaction (low nanomolar IC50) that makes Trans-ISRIB such a potent ISR inhibitor.
In the cis configuration, the aromatic groups are on the same side, compressing the molecule into a more folded shape. This disrupts the optimal binding geometry — the two glycolamide arms can no longer span the binding pockets simultaneously, and the binding affinity drops by more than three orders of magnitude. CIS-ISRIB is, for practical purposes, biologically inactive as an ISR inhibitor at concentrations typically used in research.
Standard chemical synthesis of ISRIB produces a mixture of trans and cis isomers. The ratio depends on the synthetic route and conditions. For research-grade Trans-ISRIB, isomeric purity (trans content) should be ≥98%. For in vivo and IND-grade work, trans content should be ≥99.5%. Always verify the isomeric purity on the Certificate of Analysis (COA) before purchase — a low-purity ISRIB product contaminated with the cis isomer will exhibit reduced potency and inconsistent results.
Trans-ISRIB: The Mature Workhorse Probe
Trans-ISRIB is the original and most widely used ISR pathway inhibitor. Since its discovery in 2013, it has become the standard reference compound in hundreds of published studies. Its synthesis is well-established at scale, making it the most affordable and readily available ISRIB variant. For the majority of routine research applications — in vitro mechanism studies, acute in vivo experiments, and pilot studies — Trans-ISRIB provides the best balance of potency, reliability, and cost.
Strengths of Trans-ISRIB
- Mature, validated synthesis: Large-scale production with consistent batch-to-batch quality. Gram-to-kilogram quantities readily available with short lead times.
- Lowest unit cost: Economy of scale makes Trans-ISRIB the most affordable option — ideal for high-throughput screening, dose-response studies, and large-scale experiments.
- Extensive literature precedent: Hundreds of peer-reviewed publications validate its use, providing confidence in experimental design and facilitating manuscript acceptance.
- Adequate for short-term in vivo: The 8-hour half-life and moderate BBB penetration are sufficient for acute (single-dose) and subacute (up to 7-day) animal experiments.
- Flexible formulation: Good solubility in DMSO and compatibility with standard vehicles (CMC-Na, PEG-300, liposomes).
Limitations of Trans-ISRIB
- Moderate BBB penetration: The brain/plasma ratio of 0.3 means that only ~30% of plasma drug concentration reaches brain tissue — insufficient for chronic CNS studies requiring sustained therapeutic brain levels.
- Shorter half-life: The 8-hour plasma half-life requires twice-daily dosing for continuous ISR inhibition, increasing animal handling stress and experimental variability.
- Not IND-ready: The maximum achievable purity (98–99%) and impurity profile are not sufficient for GLP repeat-dose toxicity studies intended for regulatory submission.
- Declining brain penetration in aged models: In aged animals with compromised cerebrovascular function, BBB penetration drops further, limiting utility in aging and neurodegeneration research.
Trans-ISRIB is the go-to probe for in vitro cell experiments, high-throughput screening, acute in vivo dosing (≤7 days), and pilot/feasibility studies. It should be the default choice for any new ISR pathway investigation unless specific in vivo CNS or chronic dosing requirements justify upgrading to ISRIB A-17.
CIS-ISRIB: The Negative Control Isomer
CIS-ISRIB is the cis-stereoisomer of ISRIB. It shares the same molecular formula and nearly identical physicochemical properties (molecular weight, solubility, logP) with Trans-ISRIB but is essentially inactive as an ISR inhibitor. This makes it an ideal negative control compound for ISR pathway experiments.
The Value of a Stereochemical Negative Control
In rigorous experimental design, demonstrating that a biological effect is specifically mediated by the intended target — rather than by off-target activity, solvent effects, or generic physicochemical properties of the compound — is essential. CIS-ISRIB provides this control for ISRIB-based experiments.
Because CIS-ISRIB has the same molecular weight, similar solubility, and comparable logP as Trans-ISRIB, it controls for:
- Off-target effects: Any biological effect seen with Trans-ISRIB but not with CIS-ISRIB can be attributed to ISR pathway modulation (eIF2B binding), not to off-target interactions.
- Solvent/vehicle artifacts: Since both isomers are dissolved in the same vehicle at the same concentration, CIS-ISRIB controls for solvent-related effects on cells or animals.
- General physicochemical effects: Membrane partitioning, protein binding, and other non-specific interactions are similar between the two isomers, so differences in biological outcomes reflect target-specific activity.
For publication-quality ISR pathway experiments, include CIS-ISRIB at the same concentration as Trans-ISRIB (or the ISRIB derivative being used) as a parallel treatment arm. This is increasingly expected by reviewers at top-tier journals (Nature, Cell, Science) and strengthens the causal link between ISR inhibition and observed phenotypes.
When to Use CIS-ISRIB
- Key mechanism-confirmation experiments: When you need to prove that an observed effect is ISR-dependent.
- In vivo proof-of-concept studies: Running a CIS-ISRIB arm alongside Trans-ISRIB in animal experiments to control for non-specific drug effects.
- Dose-response validation: Confirming that the dose-response curve is specific to ISR inhibition rather than a general cytotoxic or cytostatic effect.
- Manuscript preparation: Reviewers increasingly request isomeric controls for stereochemically active compounds.
ISRIB A-15: The In Vitro Screening Specialist
ISRIB A-15 is a derivative optimized for maximum in vitro potency. It features structural modifications that enhance binding affinity to eIF2B in cell-based assays, achieving an IC50 approximately 2.5-fold lower than Trans-ISRIB. However, these same modifications reduce metabolic stability and BBB penetration, making A-15 less suitable for in vivo work. It is maintained as a small-batch, in-stock product for researchers who need enhanced in vitro activity.
Strengths of ISRIB A-15
- Enhanced in vitro potency: Lower IC50 (~2 nM vs. ~5 nM for Trans-ISRIB) means less compound needed per assay — important for expensive cell lines or limited primary cell preparations.
- Optimized for high-throughput screening: The enhanced potency improves the signal-to-noise ratio in 96-well and 384-well plate formats, reducing false-negative rates in library screens.
- In stock despite small demand: While market demand is smaller than Trans-ISRIB, A-15 is maintained in inventory to serve specialized screening needs without long lead times.
- Cost-effective for screening scale: Although the unit price is higher than Trans-ISRIB, the enhanced potency means lower working concentrations, so the per-assay cost remains reasonable.
Limitations of ISRIB A-15
- Shorter half-life (6h): The structural modifications that boost in vitro activity accelerate metabolic clearance, making A-15 suboptimal for in vivo studies requiring sustained drug exposure.
- Low BBB penetration: The brain/plasma ratio of 0.4 is insufficient for CNS-targeted in vivo research.
- Small-batch production: Due to limited market demand, A-15 is produced in smaller batches, which contributes to a higher unit price than Trans-ISRIB.
- Not suitable for chronic in vivo dosing: The short half-life and lower metabolic stability preclude use in long-term animal studies.
ISRIB A-15 is the probe of choice for large-scale high-throughput screening campaigns, short-term primary neuron cultures, and mechanistic studies where maximal in vitro potency is critical. It is not recommended for in vivo work — use Trans-ISRIB for acute in vivo or ISRIB A-17 for chronic in vivo studies instead.
ISRIB A-17: The Premium In Vivo CNS Probe
ISRIB A-17 is the most advanced ISRIB derivative, engineered with a fluoro-chloro disubstituted aromatic core specifically for chronic in vivo CNS research. The fluorine atom blocks cytochrome P450-mediated oxidation, extending the plasma half-life to 14 hours. The chlorine substituent increases lipophilicity, boosting BBB penetration to 2.1× the brain exposure of Trans-ISRIB. ISRIB A-17 is the only ISRIB variant validated for 90–180 day chronic dosing and IND-track safety evaluation.
Strengths of ISRIB A-17
- Superior BBB penetration: 2.1× higher brain tissue drug exposure than Trans-ISRIB. The only ISRIB variant that maintains efficient brain enrichment in aged animal models with declined cerebrovascular function.
- Extended metabolic stability: 14-hour plasma half-life supports once-daily oral administration, reducing animal handling stress by 50% compared to twice-daily regimens required for Trans-ISRIB.
- Ultra-low impurity profile: The fluorinated modification produces only a single, controllable byproduct during synthesis. Can reach ≥99.5% purity — the only ISRIB variant suitable for GLP repeat-dose toxicity studies.
- Validated long-term safety: Continuous administration for 90–180 days shows no hepatic, renal, or pancreatic accumulation toxicity.
- IND-ready: Complete documentation package (COA, HPLC, NMR, MS, impurity spectrum, process traceability) available for regulatory submission.
- Formulation versatility: Compatible with liposomes, PLGA nanoparticles, hydrogels, and simple oral suspensions for flexible delivery research.
Limitations of ISRIB A-17
- Highest unit cost: The rare fluorinated raw materials, low-temperature precision synthesis, and strict impurity control contribute to a unit price significantly higher than Trans-ISRIB.
- Small-batch production: Market demand is smaller than for Trans-ISRIB, so production runs are smaller and less frequent. However, gram-scale stock is maintained for immediate shipment.
- Over-specification for routine in vitro work: Using A-17 for simple cell culture experiments is unnecessary — the enhanced in vivo properties (BBB penetration, half-life) provide no benefit in vitro, and the higher cost is wasteful.
ISRIB A-17 is the probe of choice for chronic in vivo CNS studies (30+ days), neurodegeneration models (AD, ALS, prion disease), aged animal models, ischemic stroke recovery research, blood-labyrinth barrier neuroprotection, and any project intended for IND submission. If your research involves the brain and requires sustained drug exposure, A-17 is not an upgrade — it is the only appropriate choice.
Comprehensive Four-Way Comparison
The following table consolidates all critical parameters across the four ISRIB variants. Use it as a quick reference when evaluating which compound best matches your experimental requirements.
| Parameter | Trans-ISRIB | CIS-ISRIB | ISRIB A-15 | ISRIB A-17 |
|---|---|---|---|---|
| Role | Standard workhorse probe | Negative control isomer | High-activity in vitro probe | Premium in vivo CNS probe |
| CAS Number | 1597403-47-2 | 1597403-48-3 | Proprietary | Proprietary |
| Stereochemistry | Trans (E) — active | Cis (Z) — inactive | Trans derivative | Trans derivative (fluoro-chloro) |
| ISR Inhibitory Activity | IC50 ~5 nM | >1000× weaker (negligible) | IC50 ~2 nM (enhanced) | IC50 ~5 nM (comparable) |
| Plasma Half-Life | ~8 h | N/A (inactive) | ~6 h | 14 h |
| Brain/Plasma Ratio | 0.3 | N/A | 0.4 | 0.63 |
| Relative Brain Exposure | 1.0× | N/A | 1.3× | 2.1× |
| BBB in Aged Models | Poor | N/A | Moderate | Excellent |
| Max Purity | ≥99% | ≥98% | ≥99% | ≥99.5% |
| Long-Term Safety (90+ days) | Not recommended | N/A | Not recommended | Validated |
| IND-Ready | No | No | No | Yes |
| Primary Application | In vitro / acute in vivo | Negative control | High-throughput screening | Chronic in vivo / IND |
| Production Scale | Large-scale (mature) | On-demand | Small-batch (in stock) | Small-batch (in stock) |
| Cost Level | $ | $ | $$ | $$$ |
Trans-ISRIB
Entry-level workhorse. Mature product, lowest unit price, extensive literature. Best for routine in vitro work and acute in vivo experiments (≤7 days). In Vitro / Acute In Vivo
CIS-ISRIB
Stereochemical negative control. Same formula, inactive as ISR inhibitor. Essential for rigorous mechanism-confirmation experiments and publication-quality controls. Negative Control
ISRIB A-15
High-activity in vitro specialist. Enhanced potency (IC50 ~2 nM) for high-throughput screening. Short half-life and low BBB penetration limit in vivo use. In Vitro Screening
ISRIB A-17
Premium in vivo CNS probe. 2.1× brain exposure, 14-hour half-life, IND-grade purity. Purpose-built for chronic neurodegeneration, TBI, stroke, and IND-track safety studies. Premium In Vivo
Pricing & Market Positioning
Understanding the pricing structure of ISRIB variants is essential for research budget planning. The four compounds occupy distinct positions in a value pyramid that reflects their production complexity, market demand, and application scope.
For a typical research project, consider a tiered procurement strategy: use Trans-ISRIB for initial in vitro screening and pilot studies (lowest cost), then upgrade to ISRIB A-17 only for the in vivo confirmation phase (when BBB penetration and chronic safety are essential). Purchase CIS-ISRIB in small quantities (10–20mg) for key mechanism-confirmation experiments. This approach optimizes the cost-to-data-quality ratio across the full research workflow.
Selection Decision Guide
Use the following step-by-step decision framework to determine which ISRIB variant (or combination) is right for your experimental context.
Is your experiment in vitro (cell culture, cell-free assay)?
If yes → Start with Trans-ISRIB (research grade, ≥98%). For high-throughput screening requiring maximal potency, upgrade to ISRIB A-15. Include CIS-ISRIB as a negative control for key experiments. ISRIB A-17 is not necessary for purely in vitro work.
Is your experiment in vivo but short-term (single dose or ≤7 days)?
If yes → Use Trans-ISRIB at in vivo screening grade (≥99% purity, trans isomer ≥99.5%). The 8-hour half-life and moderate BBB penetration are adequate for acute experiments. Consider including a CIS-ISRIB arm for mechanism confirmation.
Is your experiment chronic in vivo (30+ days) or CNS-targeted?
If yes → ISRIB A-17 is the only appropriate choice. Its 14-hour half-life, 2.1× brain exposure, and validated 90–180 day safety profile are essential. Trans-ISRIB and A-15 will produce inadequate brain drug levels and inconsistent efficacy over chronic dosing periods.
Does your project involve aged animal models (18+ months)?
If yes → ISRIB A-17 is required. Aged animals have compromised cerebrovascular function that reduces BBB transport. A-17's optimized lipophilicity ensures brain enrichment even in aged models, where Trans-ISRIB brain penetration drops to negligible levels.
Is your project intended for IND submission or regulatory toxicology?
If yes → ISRIB A-17 at IND high-purity grade (≥99.5%) is mandatory. Only A-17 has the impurity profile, process traceability, and documentation package to support GLP repeat-dose toxicity studies. No other ISRIB variant meets ICH Q3A impurity thresholds for regulatory submission.
Do you need a negative control for publication-quality experiments?
If yes → Add CIS-ISRIB at the same concentration as your active ISRIB compound. This is increasingly expected by reviewers at top-tier journals and strengthens the causal link between ISR inhibition and observed phenotypes.
Quality, Purity & Isomeric Control
Regardless of which ISRIB variant you select, quality and purity verification is critical for reproducible research. The ISRIB family presents unique quality challenges due to the stereochemical sensitivity of the trans/cis isomerism and the structural complexity of the A-15 and A-17 derivatives.
Isomeric Purity: The Trans/Cis Ratio
For Trans-ISRIB, isomeric purity (the ratio of trans to cis isomer) is the single most important quality parameter. Standard synthesis produces a mixture; chromatographic separation yields the enriched trans isomer. Research-grade Trans-ISRIB should have trans content ≥98%, while in vivo screening grade should achieve ≥99.5%. CIS-ISRIB, conversely, should have cis content ≥98%.
Before using any ISRIB compound, verify the Certificate of Analysis (COA) for: (1) chemical purity (HPLC), (2) isomeric purity (chiral HPLC or NMR), (3) identity confirmation (NMR, MS), and (4) residual solvent content. A product with 98% chemical purity but only 90% trans isomer content is effectively only ~88% active compound — which will produce misleading dose-response data.
Purity Grade Selection
| Purity Grade | Min Purity | Trans Isomer Content | Recommended Use | Available For |
|---|---|---|---|---|
| Research Grade | ≥98% | ≥98% | In vitro cell experiments, mechanism studies, pilot screening | Trans-ISRIB, CIS-ISRIB, A-15, A-17 |
| In Vivo Screening Grade | ≥99% | ≥99.5% | Acute in vivo (≤7 days), short-term animal experiments | Trans-ISRIB, A-15, A-17 |
| IND High-Purity Grade | ≥99.5% | ≥99.8% | Chronic in vivo (30+ days), GLP toxicology, IND submission | A-17 only |
Storage & Stability
All ISRIB variants should be stored as solids at −20°C, protected from light and moisture. Under these conditions:
- Trans-ISRIB solid: Stable for 24 months. DMSO stock solutions stable for 4 months at −20°C.
- CIS-ISRIB solid: Stable for 24 months (same conditions as Trans-ISRIB).
- ISRIB A-15 solid: Stable for 18 months. DMSO stock solutions stable for 3 months at −20°C.
- ISRIB A-17 solid: Stable for 18 months. DMSO stock solutions stable for 4 months at −20°C.
Avoid repeated freeze-thaw cycles. Always allow the vial to equilibrate to room temperature before opening to prevent condensation. Discard any DMSO stock solution that shows precipitation, color change, or turbidity.
Frequently Asked Questions
Trans-ISRIB and CIS-ISRIB are geometric isomers (stereoisomers) of the same molecular compound. Trans-ISRIB has the two aromatic substituent groups on opposite sides of the central double bond, giving it potent ISR-inhibitory activity by binding and stabilizing eIF2B. CIS-ISRIB has the substituents on the same side, which disrupts the optimal binding geometry to eIF2B, rendering it essentially inactive as an ISR inhibitor. CIS-ISRIB is primarily used as a negative control in ISR pathway experiments to confirm that observed effects are ISR-specific.
Trans-ISRIB is a mature product with established large-scale synthesis routes, high market demand, and economies of scale. ISRIB A-17 requires rare fluorinated raw materials, low-temperature precision synthesis, and strict impurity control (to achieve 99.5%+ purity for IND-grade applications). The specialized production process, small batch sizes, and lower market volume all contribute to its higher unit cost. Trans-ISRIB is the entry-level probe for routine research, while ISRIB A-17 is a premium probe purpose-built for chronic in vivo CNS studies.
Yes. CIS-ISRIB is the ideal negative control for Trans-ISRIB and its derivatives. Because it shares the same molecular formula and nearly identical physicochemical properties (solubility, logP, molecular weight) but lacks ISR-inhibitory activity, any biological effect observed with Trans-ISRIB but not with CIS-ISRIB can be attributed specifically to ISR pathway modulation rather than off-target effects or solvent-related artifacts.
For routine in vitro cell experiments and high-throughput screening, Trans-ISRIB at research grade (≥98% purity) offers the best cost-performance ratio. For short-term primary neuron cultures or mechanistic studies requiring higher activity, ISRIB A-15 provides enhanced in vitro potency. ISRIB A-17 is not necessary for standard cell culture work unless the study will subsequently transition to in vivo experiments and you want to use the same compound throughout.
Yes. ISRIB A-15 is kept in stock despite smaller market demand. It is shipped in small batches (typically 10mg to 100mg quantities) to serve researchers who need higher in vitro activity than Trans-ISRIB but do not require the in vivo capabilities of ISRIB A-17. While the unit price is higher than Trans-ISRIB due to smaller batch production, the total cost for typical in vitro screening projects remains manageable because milligram quantities are sufficient.
For short-term acute animal experiments (single dose or dosing up to 7 days), Trans-ISRIB at in vivo screening grade (≥99% purity, trans-isomer content ≥99.5%) is sufficient. For chronic animal studies (30+ days), neurodegeneration models, or any project intended for IND submission, ISRIB A-17 at IND high-purity grade (≥99.5%) is strongly recommended due to its superior metabolic stability, BBB penetration, and validated long-term safety profile.
All ISRIB variants should be stored as solids at -20°C, protected from light and moisture, for up to 24 months (Trans-ISRIB) or 18 months (ISRIB A-15 and A-17). DMSO stock solutions are stable for 4 months at -20°C. Avoid repeated freeze-thaw cycles. Always allow the vial to equilibrate to room temperature before opening to prevent condensation. CIS-ISRIB follows the same storage conditions as Trans-ISRIB.
While technically possible, switching ISRIB variants mid-project is not recommended without bridging studies. Each variant has a distinct pharmacokinetic profile (half-life, peak concentration, brain exposure), so dose-equivalent comparisons require careful recalibration. If you anticipate transitioning from in vitro to in vivo work, consider using ISRIB A-17 throughout to maintain compound consistency. If you must switch, conduct a dose-finding pilot study with the new compound before committing to the full experiment.
Need Help Selecting the Right ISRIB Variant?
Our technical team can help you match the right ISRIB compound to your experimental design, provide detailed COA documentation, and offer formulation guidance for any research context.
Request a QuoteAll ISRIB compounds described in this article are provided for research use only and are not intended for human consumption, clinical diagnosis, or therapeutic use. ISRIB and its derivatives have not been evaluated by the FDA or other regulatory authorities for safety or efficacy in humans. All animal research must be conducted in accordance with institutional IACUC protocols and applicable regulations.
Conclusion
The ISRIB family is not a one-size-fits-all toolkit. Each variant occupies a specific niche in the research workflow, and selecting the wrong compound can compromise data quality, waste resources, or produce misleading results. The key principles are straightforward:
- Trans-ISRIB is the default choice for routine in vitro work and acute in vivo experiments. Its mature production, low cost, and extensive literature make it the most accessible and reliable entry point into ISR pathway research.
- CIS-ISRIB is an essential negative control for publication-quality experiments. Its value lies not in what it does, but in what it does not do — providing the stereochemical evidence that your biological effects are ISR-specific.
- ISRIB A-15 fills the gap when maximal in vitro potency is needed for high-throughput screening or mechanistic studies. Its small-batch production and moderate pricing make it accessible for specialized screening projects.
- ISRIB A-17 is the premium probe for chronic in vivo CNS research and IND-track drug development. Its superior BBB penetration, extended half-life, and IND-grade purity are not luxuries — they are essential requirements for the demanding experimental contexts it was designed to serve.
By matching the ISRIB variant to your specific experimental context — rather than defaulting to the cheapest or most potent option — you ensure that your research dollars are spent efficiently, your data are robust and publishable, and your experimental design meets the standards expected by reviewers and regulators alike.